STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma
- Registration Number
- NCT01367665
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This single-arm, open-label, multi-center study will evaluate the safety and efficacy of vismodegib (GDC-0449) in patients with locally advanced or metastatic basal cell carcinoma. Patients will receive oral doses of vismodegib 150 mg once daily until disease progression or unacceptable toxicity.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1232
- Adult patients, >/=18 years of age
- Metastatic or locally advanced basal cell carcinoma considered inoperable or that surgery is contraindicated and radiotherapy is contraindicated or inappropriate
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
- Concurrent anti-tumor therapy
- Completion of the most recent anti-tumor therapy less than 21 days prior to the initiation of treatment
- Uncontrolled medical illness
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Vismodegib - Metastatic vismodegib Participants received vismodegib 150 mg orally once a day until one of the following occurs: Disease progression, intolerable toxicity most probably attributable to vismodegib, consent withdrawal, death, study termination by the Sponsor, or other reason deemed by the Investigator. vismodegib: 150 mg once daily until disease progression or unacceptable toxicity Vismodegib - Locally Advanced vismodegib Participants received vismodegib 150 mg orally once a day until one of the following occurs: Disease progression, intolerable toxicity most probably attributable to vismodegib, consent withdrawal, death, study termination by the Sponsor, or other reason deemed by the Investigator. vismodegib: 150 mg once daily until disease progression or unacceptable toxicity
- Primary Outcome Measures
Name Time Method Percentage of Participants Who Died Due to Adverse Events, Disease Progression or Other Reasons Baseline to the data cut-off of 14 June 2017 (up to 6 years) Reasons for "other" included "unknown," "natural causes," "cardiac decompensation," "general state alteration," "deterioration of general state," "clinical deterioration taking into consideration patient's age," "old age," and "disease progression of mediastinal squamous cell carcinoma (SCC)."
Percentage of Participants Who Report a Shift in NCI CTCAE Grades to 3/4 in Hematology and Biochemistry Laboratory Parameters Baseline to the data cut-off of 14 June 2017 (up to 6 years) Exposure to Study Treatment - Dose Intensity Baseline to the data cut-off of 14 June 2017 (up to 6 years) Dose intensity was defined as the percentage of actual number of doses received versus planned.
Exposure to Study Treatment: Duration on Treatment Baseline to the data cut-off of 14 June 2017 (up to 6 years) Duration on treatment was the number of days between first and last dose of study treatment.
Percentage of Participants Who Experienced Any Adverse Events (AEs), AEs Grade 3 or 4, AEs Leading to Drug Interruptions or Discontinuations and Any Serious Adverse Events (SAEs) Baseline to the data cut-off of 14 June 2017 (up to 6 years) Adverse events were graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activity of daily living with inability to perform bathing, dressing and undressing, feeding self, using the toilet, taking medications but not bedridden. Grade 4: An immediate threat to life. Urgent medical intervention is required in order to maintain survival.
- Secondary Outcome Measures
Name Time Method Progression-Free Survival (PFS) Baseline to the data cut-off of 14 June 2017 (up to 6 years) PFS was defined as the time interval between the date of the first therapy and the date of progression or death for any causes, whichever occurs first. Disease progression was assessed by the investigator.
Overall Survival (OS) Baseline to the data cut-off of 14 June 2017 (up to 6 years) OS was defined as the time from the date of first treatment to the date of death, regardless of the cause of death.
Duration of Response Baseline to the data cut-off of 14 June 2017 (up to 6 years) Duration of response was defined as the time interval between the date of the earliest qualifying response (CR or PR) and the date of disease progression or death for any cause. Median duration of response was estimated using Kaplan-Meier estimates.
Change From Baseline Scores of Skindex-16 Questionnaire Domains of Emotion, Function and Symptom Baseline to the data cut-off date of 14 June 2017 (up to 6 years). The Skindex-16 questionnaire includes three domains for the assessment of the effects of skin disease on participants' quality of life: symptoms, emotions and function. For each domain, responses from the questionnaire were transformed to a linear scale of 100 varying from 0 (never bothered, i.e., best) to 100 (always bothers, i.e., worst).
Best Overall Response Rate (BORR) Baseline to the data cut-off of 14 June 2017 (up to 6 years) BORR was defined as the percentage of participants achieving either a complete response (CR) or a partial response (PR) as assessed by the Investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) required a reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time to Response Baseline to the data cut-off of 14 June 2017 (up to 6 years) Time to response was defined as the interval between the date of first treatment and the date of first documentation of confirmed CR or PR (whichever occur first).
Percentage of Participants With a ≥ 30% Reduction in Disease-Related Symptoms According to MDASI Scale 08-May-2013 (Protocol Version ≥ 4) to the data cut-off date of 14 June 2017 (approximately 4 years and 1 month). M.D. Anderson Symptom Inventory (MDASI) scale. The MDASI core instrument is a 19-item patient self-report questionnaire whose items comprise two scales, symptom severity and symptom interference. For 13 items (i.e., pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, difficulty remembering things, lack of appetite, drowsiness, dry mouth, sadness, vomiting, and numbness or tingling), participants were asked to rate how severe the symptoms were when "at their worst" in the last 24 hours. For the remaining 6 items, participants were asked to rate how much the symptoms have interfered with 6 areas of functioning (i.e., general activity, walking, work, mood, relations with other people, and enjoyment of life) in the last 24 hours.
Percentage of Participants With a ≥ 30% Reduction in Composite Symptom Severity Score According to MDASI Scale 08-May-2013 (Protocol Version ≥ 4) to the data cut-off date of 14 June 2017 (approximately 4 years and 1 month). M.D. Anderson Symptom Inventory (MDASI) scale. The MDASI core instrument is a 19-item patient self-report questionnaire whose items comprise two scales, symptom severity and symptom interference. For 13 items (i.e., pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, difficulty remembering things, lack of appetite, drowsiness, dry mouth, sadness, vomiting, and numbness or tingling), participants were asked to rate how severe the symptoms were when "at their worst" in the last 24 hours. For the remaining 6 items, participants were asked to rate how much the symptoms have interfered with 6 areas of functioning (i.e., general activity, walking, work, mood, relations with other people, and enjoyment of life) in the last 24 hours.
Trial Locations
- Locations (181)
Premier Specialists
🇦🇺Kogarah, New South Wales, Australia
Inst. de Oncologia Angel H. Roffo ; Servicio de Oncologia
🇦🇷Buenos Aires, Argentina
Skin and Cancer Foundation Australia
🇦🇺Westmead, New South Wales, Australia
Skin & Cancer Foundation
🇦🇺Carlton, Victoria, Australia
LKH Graz; Abteilung für allgemeine Dermatologie
🇦🇹Graz, Austria
LKH Salzburg; Universitätsklinik für Dermatologie
🇦🇹Salzburg, Austria
Medizinische Universität Wien; Univ.Klinik für Dermatologie
🇦🇹Wien, Austria
Landesklinikum St. Pölten
🇦🇹St. Pölten, Austria
UZ Leuven Gasthuisberg
🇧🇪Leuven, Belgium
Hospital das Clinicas - UFRGS
🇧🇷Porto Alegre, RS, Brazil
Clinic of Oncology, University Clinical Center Sarajevo
🇧🇦Sarajevo, Bosnia and Herzegovina
District Oncology Dispensary; Department for Oncology and Dermatology
🇧🇬Plovdiv, Bulgaria
National Specialized Hospital for Active Oncology Treatment; Dermatology Clinic
🇧🇬Sofia, Bulgaria
Western Canada Dermatology Institute
🇨🇦Edmonton, Alberta, Canada
London Regional Cancer Centre
🇨🇦London, Ontario, Canada
Cancer Care Manitoba
🇨🇦Winnipeg, Manitoba, Canada
Centre de Recherche Dermatologique du Quebec Metropolitain (CRDQ)
🇨🇦Quebec, Canada
Victoria Park MediSpa
🇨🇦Montreal, Quebec, Canada
Inst. Nacional de Cancerologia; Clinica de Seno
🇨🇴Bogota, Colombia
Riesgo De Fractura; Rheumatology
🇨🇴Bogota, Colombia
Hemato Oncologos S.A.
🇨🇴Cali, Colombia
Hospital Pablo Tobon Uribe
🇨🇴Medellin-Antioquia, Colombia
Reumalab Sas; Rheumatology
🇨🇴Medellin, Colombia
Clinical Hospital Sisters of Mercy
🇭🇷Zagreb, Croatia
Nemocnice Ceske Budejovice
🇨🇿Ceske Budejovice, Czechia
Fakultni Nemocnice Hradec Kralove; Dept of Radiotherapy & Oncology
🇨🇿Hradec Kralove, Czechia
Fakultní nemocnice Ostrava; Kožní oddělení
🇨🇿Ostrava, Czechia
Vseobecna fakultni nemocnice v Praze
🇨🇿Praha 2, Czechia
Fakultni nemocnice v Motole
🇨🇿Praha 5, Czechia
Fakultni Thomayerova Nemocnice; Onkologicke Oddeleni
🇨🇿Praha, Czechia
Fakultni nemocnice Kralovske Vinohrady
🇨🇿Praha, Czechia
Herlev Hospital; Onkologisk afdeling
🇩🇰Herlev, Denmark
Helsinki University Central Hospital; Skin & Allergy Hospital
🇫🇮Helsinki, Finland
Kuopion yliopistollinen sairaala
🇫🇮Kuopio, Finland
Hopital Saint Andre CHU De Bordeaux; Dermatologie
🇫🇷Bordeaux, France
Hopital Ambroise Pare; Sce Dermatologie
🇫🇷Boulogne-billancourt, France
Chu Site Du Bocage;Dermatologie
🇫🇷Dijon, France
Hopital Timone Adultes; Dermatologie
🇫🇷Marseille, France
Hopital Hotel Dieu Et Hme; Clinique Dermatologique
🇫🇷Nantes, France
Hopital Saint Eloi; CHU de Montpellier; Svc de Dermatologie
🇫🇷Montpellier, France
Hopital Saint Louis; Dermatologie 1
🇫🇷Paris, France
Centre Hospitalier Lyon Sud; Dermatologie
🇫🇷Pierre Benite, France
Hôpital Larrey Université Paul Sabatier; Service Dermatologie
🇫🇷Toulouse, France
Institut Gustave Roussy; Comite 5
🇫🇷Villejuif, France
Vivantes Klinikum Spandau
🇩🇪Berlin, Germany
Charité Campus Mitte; Hauttumorcentrum Charité (HTCC); Klinik für Dermatologie, Venerologie und Alle
🇩🇪Berlin, Germany
Elbekliniken Buxtehude; Klinik für Dermatologie
🇩🇪Buxtehude, Germany
Universitätsklinikum "Carl Gustav Carus"; Klinik und Poliklinik für Dermatologie
🇩🇪Dresden, Germany
Universitätsklinikum Essen
🇩🇪Essen, Germany
Klinik Johann Wolfgang von Goethe Uni; Klinik für Dermatologie, Venerologie und Allergologie
🇩🇪Frankfurt, Germany
Universitätsklinikum Freiburg Universitäts-Hautklinik
🇩🇪Freiburg, Germany
Universitätsmedizin Greifswald; Klinik für MKG-Chirurgie und Plastische Operationen
🇩🇪Greifswald, Germany
Universitätsklinikum Hamburg-Eppendorf Zentrum f.Innere Medizin Klinik f.Dermatologie
🇩🇪Hamburg, Germany
Klinikum Kassel; Hautklinik
🇩🇪Kassel, Germany
Universitätsklinikum Heidelberg
🇩🇪Heidelberg, Germany
UNI-Klinikum Campus Kiel Klinik f.Dermatologie Tagesklinik f.Dermatologie
🇩🇪Kiel, Germany
Uni Schleswig-Holstein; Klinik für Dermatologie, Allergologie und Venerologie (Hautklinik)
🇩🇪Lübeck, Germany
Klinikum d.Stadt Ludwigshafen Hautklinik
🇩🇪Ludwigshafen, Germany
Universitätsklinikum Magdeburg; Hautklinik; Klinik für Dermatologie und Venerologie
🇩🇪Magdeburg, Germany
Klinikum Mannheim Klinik fuer Dermatologie, Venerologie und Allergologie
🇩🇪Mannheim, Germany
Klinik der Uni zu Köln; Klinik & Poliklinik fuer Dermatologie & Venerologie
🇩🇪Köln, Germany
Klinikum der LMU München; Klinik und Poliklinik für Dermatologie und Allergologie
🇩🇪München, Germany
Universitätsklinikum Münster; Klinik für Hautkrankheiten; Allgemeine Dermatologie und Venerologie
🇩🇪Muenster, Germany
Klinikum rechts der Isar der TU München; Klinik & Poliklinik für Dermatologie und Allergologie
🇩🇪München, Germany
Klinikum Nürnberg Nord; Hautklinik; Klinik für Dermatologie
🇩🇪Nürnberg, Germany
Harzklinikum Dorothea Christiane Erxleben GmbH; Klinik für Dermatologie und Allergologie
🇩🇪Quedlinburg, Germany
Universitätsklinikum Regensburg; Klinik und Poliklinik für Dermatologie
🇩🇪Regensburg, Germany
Universitaets-Hautklinik Tuebingen
🇩🇪Tübingen, Germany
Laiko General Hospital; 1St Pathological Clinic
🇬🇷Athens, Greece
Universitätsklinikum Würzburg; Klinik und Poliklinik für Dermatologie Venerologie u. Allergologie
🇩🇪Würzburg, Germany
Univ General Hosp Heraklion; Medical Oncology
🇬🇷Heraklion, Greece
Euromedical General Clinic of Thessaloniki; Oncology Department
🇬🇷Thessaloniki, Greece
University General Hospital of loannina; Dermatology and Venereal Diseases Clinic
🇬🇷Ioannina, Greece
Orszagos Onkologiai Intezet; B Belgyogyaszati Osztaly
🇭🇺Budapest, Hungary
Semmelweis Egyetem; Bor-, Nemikortani es Boronkologiai Klinika
🇭🇺Budapest, Hungary
Cork University Hospital; Dermatology Dept
🇮🇪Cork, Ireland
Debreceni Egyetem Klinikai Központ; Bőrgyógyászati Klinika
🇭🇺Debrecen, Hungary
Kaposi Mor Teaching Hospital
🇭🇺Kaposvár, Hungary
St Vincent'S Uni Hospital; Medical Oncology
🇮🇪Dublin, Ireland
Szegedi Tud.Egyetem Szent-Gyorgyi Albert Klin.Kozp.
🇭🇺Szeged, Hungary
Rambam Medical Center
🇮🇱Halfa, Israel
Hadassah University Hospital - Ein Kerem
🇮🇱Jerusalem, Israel
Rabin Medical Center-Beilinson Campus
🇮🇱Petach Tikva, Israel
Sheba Medical Center; Tel Hashomer
🇮🇱Ramat Gan, Israel
Ospedale San Salvatore (ASL-01); Dip. di Dermatologia U.O.S. di Dermatologia Oncol
🇮🇹L'Aquila, Abruzzo, Italy
Policlinico Sant'Orsola Malpighi; U.O. Dermatologia
🇮🇹Bologna, Emilia-Romagna, Italy
I.R.S.T. Srl - Meldola - FC; Day Hospital Oncologico
🇮🇹Meldola, Emilia-Romagna, Italy
Azienda Ospedaliera Umberto I; Clinica Dermatologica
🇮🇹Roma, Lazio, Italy
Fondazione Ptv Policlinico Tor Vergata; Dermatologia
🇮🇹Roma, Lazio, Italy
Istituto Dermatologico San Gallicano IRCCS; Dermatologia Oncolgica
🇮🇹Roma, Lazio, Italy
Istituto Dermopatico dell'Immacolata (IDI)-IRCCS; IV Divisione Oncologica e Dermatologia Oncologica
🇮🇹Roma, Lazio, Italy
IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST); Oncologia Medica A
🇮🇹Genova, Liguria, Italy
Università di Brescia; Dipartimento di Dermatologia
🇮🇹Brescia, Lombardia, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori;S.S. Trattamento MedicoTumori dellaTesta e delCollo
🇮🇹Milano, Lombardia, Italy
Irccs Istituto Europeo Di Oncologia (IEO); Oncologia Medica
🇮🇹Milano, Lombardia, Italy
Asst Grande Ospedale Metropolitano Niguarda; Dipartimento Di Ematologia Ed Oncologia
🇮🇹Milano, Lombardia, Italy
A.O.U. Ospedali Riuniti Umberto I-G.M.Lancisi-G.Salesi Ancona;S.O.D. MED.Interna-Clinica Oncologica
🇮🇹Ancona, Marche, Italy
Ospedale Armando Businco; Dermatologia
🇮🇹Cagliari, Sardegna, Italy
Fondazione Del Piemonte Per L'oncologia Ircc Di Candiolo; Dipartimento Oncologico
🇮🇹Candiolo, Piemonte, Italy
Ospedale Antonio Perrino; Oncologia Medica
🇮🇹Brindisi, Puglia, Italy
A.O.U. Senese Policlinico Santa Maria Alle Scotte
🇮🇹Siena, Toscana, Italy
Ospedale IOT- Palagi Dermatologia 2
🇮🇹Firenze, Toscana, Italy
National Cancer Institute
🇱🇹Vilnius, Lithuania
Hospital General de México
🇲🇽Mexico City, Mexico CITY (federal District), Mexico
IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Seconda
🇮🇹Padova, Veneto, Italy
LUMC; Dermatologie
🇳🇱Leiden, Netherlands
Academ Ziekenhuis Groningen; Medical Oncology
🇳🇱Groningen, Netherlands
Maastricht University Medical Centre; Dermatologie
🇳🇱Maastricht, Netherlands
Erasmus MC; Dermatology
🇳🇱Rotterdam, Netherlands
Oslo Universitetssykehus HF; Radiumhospitalet
🇳🇴Oslo, Norway
Waitemata District Health; General Surgery
🇳🇿Takapuna, New Zealand
DERMED Centrum Medyczne; Sp zoo
🇵🇱Lodz, Poland
Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii
🇵🇱Gdańsk, Poland
Centrum Diagnostyki Znamion
🇵🇱Poznan, Poland
Centrum Onkologii - Instytut im. Marii Sklodowskiej-Curie; Klinika Onkologiczna
🇵🇱Warsaw, Poland
IPO do Porto; Servico de Oncologia Medica
🇵🇹Porto, Portugal
Institutul Oncologic Prof. Dr. Al. Trestioreanu Bucuresti
🇷🇴Bucuresti, Romania
Prof. Dr. I. Chiricuta Institute of Oncology
🇷🇴Cluj Napoca, Romania
Oncology Center Sf. Nectarie
🇷🇴Craiova, Romania
S.C. Life Search S.R.L; Medical Oncology Clinic
🇷🇴Timisoara, Romania
Spital Clinic Judetean Mures; Oncologie
🇷🇴Targu Mures, Romania
FSBI"National Medical Research Center of Oncology named after N.N.Petrov" MHRF
🇷🇺St Petersburg, Leningrad, Russian Federation
FSBI "National Medical Research Center of Oncology N.N. Blokhin"
🇷🇺Moscow, Russian Federation
Moscow city oncology hospital #62 of Moscow Healthcare Department
🇷🇺Moscow, Russian Federation
Saint-Petersburg City Clinical Oncology Dispensary
🇷🇺St Petersburg, Russian Federation
Institute for Oncology and Radiology of Serbia; Medical Oncology
🇷🇸Belgrade, Serbia
Military Medical Academy
🇷🇸Belgrade, Serbia
Fakultna Nemocnica Roosevelta
🇸🇰Banska Bystrica, Slovakia
Institute of Oncology Ljubljana
🇸🇮Ljubljana, Slovenia
Hospital de Gran Canaria Dr. Negrin; Servicio de Dermatologia
🇪🇸Las Palmas de Gran Canaria, LAS Palmas, Spain
Hospital Universitario Son Espases; Servicio de Oncologia
🇪🇸Palma De Mallorca, Islas Baleares, Spain
Clinica Universitaria de Navarra; Servicio de Dermatologia
🇪🇸Pamplona, Navarra, Spain
Hospital de la Santa Creu i Sant Pau; Servicio de Dermatologia
🇪🇸Barcelona, Spain
Complejo Hospitalario Nuestra Señora de la Candelaria; Servicio de Dermatologia
🇪🇸Santa Cruz de Tenerife, Tenerife, Spain
Hospital de Cruces; Servicio de Oncologia
🇪🇸Bilbao, Vizcaya, Spain
Hospital Reina Sofia; Servicio de dermatología
🇪🇸Cordoba, Spain
Hospital Clinic i Provincial; Servicio de dermatología
🇪🇸Barcelona, Spain
Complejo Asistencial Universitario de Leon; Servicio de Oncologia
🇪🇸Leon, Spain
Hospital Universitario Virgen de las Nieves; Servicio de Oncologia
🇪🇸Granada, Spain
Hospital General Universitario de Guadalajara; Servicio de Dermatologia
🇪🇸Guadalajara, Spain
Hospital General Universitario Gregorio Marañon; Servicio de Oncologia
🇪🇸Madrid, Spain
Hospital Universitario Virgen Macarena; Servicio de Oncologia
🇪🇸Sevilla, Spain
Hospital Universitario 12 de Octubre; Servicio de Oncologia
🇪🇸Madrid, Spain
Hospital General Universitario J.M Morales Meseguer; Servicio de Dermatologia
🇪🇸Murcia, Spain
Complejo Hospitalario de Toledo- H. Virgen de la Salud; Servicio de Dermatologia
🇪🇸Toledo, Spain
Hospital General Universitario de Valencia; Servicio de oncologia
🇪🇸Valencia, Spain
Instituto Valenciano Oncologia; Oncologia Medica
🇪🇸Valencia, Spain
Hospital Universitario Miguel Servet; Servicio Dermatologia
🇪🇸Zaragoza, Spain
Skånes Onkologiska Klinik, Universitetssjukhuset
🇸🇪Lund, Sweden
Karolinska Universitetssjukhuset, Solna
🇸🇪Stockholm, Sweden
Ankara Numune Training and Research Hospital; Dermatology
🇹🇷Ankara, Turkey
Universitätsspital Zürich; Dermatologische Klinik
🇨🇭Zürich, Switzerland
Gazi Universitesi Tip Facultesi; Dept. of Dermatology
🇹🇷Ankara, Turkey
Istanbul Uni of Medicine Faculty; Oncology Dept
🇹🇷Istanbul, Turkey
Dokuz Eylul University Medicine Faculty; Dermatology
🇹🇷Izmir, Turkey
Hacettepe Uni Medical Faculty Hospital; Oncology Dept
🇹🇷Sıhhiye, Ankara, Turkey
Addenbrookes Hospital; Cambridge Cancer Trials Centre, S4 Box 279
🇬🇧Cambridge, United Kingdom
Western Infirmary; Division of Cardiovascular and Medical Sciences
🇬🇧Glasgow, United Kingdom
St Thomas Hospital
🇬🇧London, United Kingdom
Royal Marsden Hospital - London
🇬🇧London, United Kingdom
Freeman Hospital; Northern Centre For Cancer Care
🇬🇧New Castle Upon Tyne, United Kingdom
Salford Royal NHS Foundation Trust
🇬🇧Salford, United Kingdom
The Royal Marsden Hospital
🇬🇧Sutton, United Kingdom
Fundacion Hospital de Alcorcon; Servicio de Dermatologia
🇪🇸Alcorcon, Madrid, Spain
Hospital Universitario del Sureste; Servicio de Dermatologia
🇪🇸Arganda del Rey, Madrid, Spain
CMAX A division of IDT Australia Limited
🇦🇺Adelaide, South Australia, Australia
Istituto Nazionale Tumori Fondazione G. Pascale
🇮🇹Napoli, Campania, Italy
Hospital Univ. Central de Asturias; Servicio de Dermatologia
🇪🇸Oviedo, Asturias, Spain
University Clinical Center of the Republic of Srpska
🇧🇦Banja Luka, Bosnia and Herzegovina
Hopital Claude Huriez; Sce Dermatologie
🇫🇷Lille, France
Dr. Nowell Solish Cosmetic Dermatology
🇨🇦Toronto, Ontario, Canada
Hospital de Cancer de Barretos
🇧🇷Barretos, SP, Brazil
Instituto do Cancer do Estado de Sao Paulo - ICESP
🇧🇷Sao Paulo, SP, Brazil
Medizinische Hochschule Hannover; Klinik für Dermatologie, Allergologie und Venerologie
🇩🇪Hannover, Germany
Klinikum am Gesundbrunnen; Tumorzentrum
🇩🇪Heilbronn, Germany
Universitätsklinikum Marburg Klinik f. Dermatologie
🇩🇪Marburg, Germany
Klinikum Dortmund gGmbH Klinikzentrum Mitte
🇩🇪Dortmund, Germany
Universitätsklinikum Düsseldorf; Hautklinik
🇩🇪Düsseldorf, Germany
HELIOS Klinikum Erfurt; Klinik für Dermatologie & Allergologie
🇩🇪Erfurt, Germany
Andreas Syggros Hospital; 1st University Dermatology Clinic; Oncology Department
🇬🇷Athens, Greece
IRCCS Istituto Clinico Humanitas; Farmacia
🇮🇹Rozzano, Lombardia, Italy